article thumbnail

Chanelle McCoy Granted Approval For Significant Ultra Pure Synthetic CBD Phase III Efficacy Clinical Trial

Cannabis Law Report

PRESS RELEASE UK company Chanelle McCoy Health granted Ethics Approval to commence Phase III Efficacy Clinical Trial for the treatment of Sleep Disturbance CMH-CBD-001 using their Ultra Pure Synthetic Cannabinoid (CBD) formulation with pharmaceutical grade FDA registered raw material.

article thumbnail

Incannex (ASX: IHL) partners with Procaps to develop cannabis medicine for clinical trial on sleep apnea

Cannabis Law Report

Incannex Healthcare Limited (ASX: IHL) has engaged pharmaceutical manufacturing company Procaps S.A The agreement between the two companies will see Procaps making IHL-42X for Incannex’s Phase 2, Phase 3, and open-label clinical trials. According to an article from the Lancet, sleep apnea affects 936 million adults globally.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Tryp Therapeutics Announces Phase 2a Clinical Trial for Fibromyalgia with the University of Michigan

Cannabis Law Report

The study is expected to be the world’s first Phase 2a clinical trial evaluating the efficacy of psilocybin and psychotherapy to treat fibromyalgia. The open-label Phase 2a clinical trial will evaluate the efficacy of TRYP-8802, an oral formulation of synthetic psilocybin, in tandem with psychotherapy for treating fibromyalgia.

article thumbnail

Could CBN really help you sleep? Consumer study data suggest yes.

The Cannigma

CBN has made headlines and claimed shelf space as the next best cannabinoid for sleep. MoreBetter, creators of the Releaf App, is using this real world data to push back against the claim that there’s no evidence that CBN can help people sleep. It also, allegedly, helps with sleep (more on that below). Back to our study.

Sleep 133
article thumbnail

IGC Completes Cohort 2 of its Phase 1 THC-Based Clinical Trial on Alzheimer’s Patients

Cannabis Law Report

IGC”) (NYSE American: IGC) announces today that it has completed Cohort 2 of its Phase 1 clinical trial on IGC’s tetrahydrocannabinol (“THC”)-based investigational new drug, IGC-AD1, intended to alleviate the symptoms of individuals suffering from Alzheimer’s disease. This Phase 1 trial is currently testing IGC-AD1 for safety.

article thumbnail

Unlocking the Potential of CBD: Exploring The Benefits of CBD in Medical Marijuana

MMJ Recs

Furthermore, ongoing clinical trials are investigating CBD’s efficacy in treating conditions such as multiple sclerosis, Parkinson’s disease, and substance abuse disorders. Sleep disturbances are prevalent among individuals of all ages and can have a profound impact on overall health and well-being.

CBD 52
article thumbnail

What is CBN (Cannabinol)? How does the natural byproduct of THC work?

The Cannigma

Of course, this plant is now known to be marijuana (or Type I cannabis), which is still commonly used for sleep and analgesia today. CBN has been receiving a lot of attention for its ability to induce sleep, as it’s frequently marketed as nature’s sleep aid. What can the current clinical trials tell us?

THC 140